IBDEI35T ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,53045,1,4,0)
 ;;=4^C44.529
 ;;^UTILITY(U,$J,358.3,53045,2)
 ;;=^5001059
 ;;^UTILITY(U,$J,358.3,53046,0)
 ;;=C44.622^^243^2659^15
 ;;^UTILITY(U,$J,358.3,53046,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53046,1,3,0)
 ;;=3^SCC Skin Right Upper Limb
 ;;^UTILITY(U,$J,358.3,53046,1,4,0)
 ;;=4^C44.622
 ;;^UTILITY(U,$J,358.3,53046,2)
 ;;=^5001070
 ;;^UTILITY(U,$J,358.3,53047,0)
 ;;=C44.629^^243^2659^6
 ;;^UTILITY(U,$J,358.3,53047,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53047,1,3,0)
 ;;=3^SCC Skin Left Upper Limb
 ;;^UTILITY(U,$J,358.3,53047,1,4,0)
 ;;=4^C44.629
 ;;^UTILITY(U,$J,358.3,53047,2)
 ;;=^5001071
 ;;^UTILITY(U,$J,358.3,53048,0)
 ;;=C44.722^^243^2659^14
 ;;^UTILITY(U,$J,358.3,53048,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53048,1,3,0)
 ;;=3^SCC Skin Right Lower Limb
 ;;^UTILITY(U,$J,358.3,53048,1,4,0)
 ;;=4^C44.722
 ;;^UTILITY(U,$J,358.3,53048,2)
 ;;=^5001082
 ;;^UTILITY(U,$J,358.3,53049,0)
 ;;=C44.729^^243^2659^5
 ;;^UTILITY(U,$J,358.3,53049,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53049,1,3,0)
 ;;=3^SCC Skin Left Lower Limb
 ;;^UTILITY(U,$J,358.3,53049,1,4,0)
 ;;=4^C44.729
 ;;^UTILITY(U,$J,358.3,53049,2)
 ;;=^5001083
 ;;^UTILITY(U,$J,358.3,53050,0)
 ;;=C44.82^^243^2659^10
 ;;^UTILITY(U,$J,358.3,53050,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53050,1,3,0)
 ;;=3^SCC Skin Overlapping Sites
 ;;^UTILITY(U,$J,358.3,53050,1,4,0)
 ;;=4^C44.82
 ;;^UTILITY(U,$J,358.3,53050,2)
 ;;=^5001089
 ;;^UTILITY(U,$J,358.3,53051,0)
 ;;=L57.8^^243^2659^22
 ;;^UTILITY(U,$J,358.3,53051,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53051,1,3,0)
 ;;=3^Skin Changes d/t Chr Exposure to Nonionizing Radiation
 ;;^UTILITY(U,$J,358.3,53051,1,4,0)
 ;;=4^L57.8
 ;;^UTILITY(U,$J,358.3,53051,2)
 ;;=^5009226
 ;;^UTILITY(U,$J,358.3,53052,0)
 ;;=L27.0^^243^2659^23
 ;;^UTILITY(U,$J,358.3,53052,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53052,1,3,0)
 ;;=3^Skin Eruption,Generalized d/t Drugs/Meds Taken Internally
 ;;^UTILITY(U,$J,358.3,53052,1,4,0)
 ;;=4^L27.0
 ;;^UTILITY(U,$J,358.3,53052,2)
 ;;=^5009144
 ;;^UTILITY(U,$J,358.3,53053,0)
 ;;=L27.1^^243^2659^24
 ;;^UTILITY(U,$J,358.3,53053,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53053,1,3,0)
 ;;=3^Skin Eruption,Localized d/t Drugs/Meds Taken Internally
 ;;^UTILITY(U,$J,358.3,53053,1,4,0)
 ;;=4^L27.1
 ;;^UTILITY(U,$J,358.3,53053,2)
 ;;=^5009145
 ;;^UTILITY(U,$J,358.3,53054,0)
 ;;=L51.1^^243^2659^29
 ;;^UTILITY(U,$J,358.3,53054,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53054,1,3,0)
 ;;=3^Stevens-Johnson Syndrome
 ;;^UTILITY(U,$J,358.3,53054,1,4,0)
 ;;=4^L51.1
 ;;^UTILITY(U,$J,358.3,53054,2)
 ;;=^336636
 ;;^UTILITY(U,$J,358.3,53055,0)
 ;;=L51.3^^243^2659^30
 ;;^UTILITY(U,$J,358.3,53055,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53055,1,3,0)
 ;;=3^Stevens-Johnson Syndrome-Toxic Epdrml Necrolysis Overlap Syndrome
 ;;^UTILITY(U,$J,358.3,53055,1,4,0)
 ;;=4^L51.3
 ;;^UTILITY(U,$J,358.3,53055,2)
 ;;=^336637
 ;;^UTILITY(U,$J,358.3,53056,0)
 ;;=Z12.83^^243^2659^19
 ;;^UTILITY(U,$J,358.3,53056,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53056,1,3,0)
 ;;=3^Screening for Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,53056,1,4,0)
 ;;=4^Z12.83
 ;;^UTILITY(U,$J,358.3,53056,2)
 ;;=^5062696
 ;;^UTILITY(U,$J,358.3,53057,0)
 ;;=Z48.817^^243^2659^33
 ;;^UTILITY(U,$J,358.3,53057,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53057,1,3,0)
 ;;=3^Surgical Aftercare Following Skin Surgery
 ;;^UTILITY(U,$J,358.3,53057,1,4,0)
 ;;=4^Z48.817
 ;;^UTILITY(U,$J,358.3,53057,2)
 ;;=^5063054
 ;;^UTILITY(U,$J,358.3,53058,0)
 ;;=L94.0^^243^2659^18
 ;;^UTILITY(U,$J,358.3,53058,1,0)
 ;;=^358.31IA^4^2
